Related Experiment Video
Updated: Jul 29, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities (2025 Version)]
Abstract:
The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, plays a crucial role in the regulation of physiological processes such as cell proliferation, migration, invasion, and angiogenesis. The MET gene is one of the key drivers in non-small cell lung cancer (NSCLC), with various forms of abnormalities including MET exon 14 (METex14) skipping mutations, MET gene amplification, MET fusions, MET protein overexpression, MET activating mutations and etc. With an increasing understanding of the mechanisms underlying MET abnormalities, therapeutic strategies targeting these abnormalities have gained significant attention, and numerous studies have confirmed that NSCLC patients with MET abnormalities can derive substantial benefits from such treatments. Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized a panel of experts to provide professional recommendations on current clinical issues in the diagnosis and treatment of MET-aberrant NSCLC, combining clinical practice experiences and evidence-based medical evidences. The "Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities (2025 Version)" has been formulated to provide standardized guidances for clinical practice in China, with the aim of optimizing the treatment outcomes. .
Insights
This expert consensus provides guidance on diagnosing and treating non-small cell lung cancer (NSCLC) with MET gene abnormalities. It aims to standardize clinical practice and improve treatment outcomes for patients with MET-aberrant NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- The MET gene is crucial for cell functions and a key driver in non-small cell lung cancer (NSCLC).
- MET gene abnormalities, including MET exon 14 skipping, are common in NSCLC.
- Targeted therapies for MET-aberrant NSCLC offer significant benefits.
Purpose:
- To establish expert recommendations for diagnosing and treating MET-aberrant NSCLC.
- To provide standardized clinical guidance based on evidence and experience.
- To optimize treatment outcomes for NSCLC patients with MET abnormalities.
Summary:
- This consensus addresses the diagnosis and treatment of NSCLC with MET abnormalities.
- It covers various MET alterations like MET exon 14 skipping mutations, gene amplification, and overexpression.
- Expert recommendations integrate clinical experience and evidence-based medicine.
Impact:
- Aims to standardize clinical practice for MET-aberrant NSCLC in China.
- Expected to improve treatment outcomes for NSCLC patients with MET abnormalities.
- Facilitates better management of a specific subset of lung cancer patients.
